A cutting-edge medical tool uses deep learning to examine brain MRI scans, aiding medical professionals in diagnosing neurodegenerative diseases like Alzheimer's and vascular dementia.

VUNO Inc.’s (Seoul, Korea) VUNO Med-DeepBrain is an AI-based brain imaging analysis medical device that analyzes brain MRI by dividing the brain into more than 100 different areas. It then offers data on the level of atrophy in each of these regions, all within just one minute. This advanced tool is particularly useful for medical professionals in detecting dementia due to neurodegenerative conditions like Alzheimer's and vascular dementia.

A recent study has shown that VUNO Med-DeepBrain is also effective in diagnosing "subjective cognitive decline," a stage that precedes the manifestation of full-blown dementia symptoms. This finding implies that the technology could be instrumental in flagging individuals who are more likely to transition from minor cognitive issues to severe dementia. The device has gained approval from the U.S. Food and Drug Administration (FDA), marking it as VUNO Inc.'s first product to achieve such certification. Looking ahead, VUNO aims to expand its presence in the U.S. healthcare market through its American subsidiary and also seeks to collaborate with global pharmaceutical firms and other organizations.

“We expect VUNO Med-DeepBrain to be the cornerstone of our expansion into the U.S. market,” said VUNO Chief Executive Officer Lee Ye-ha. “With the recent advent of next-generation dementia treatments, there is a growing demand for early diagnosis, and we will strengthen our sales efforts to rapidly expand this product in the U.S. market and contribute to solving the problem of dementia.” 

http://www.gzjiayumed.com/en/index.asp